Your session is about to expire
← Back to Search
Allogeneic Human Cardiosphere-Derived Stem Cells for Pulmonary Arterial Hypertension (ALPHA Trial)
ALPHA Trial Summary
This trial is testing whether or not using allogeneic CDCs (cellular therapy) can help reduce adverse remodeling in PAH, a progressive condition for which there is no cure.
- Pulmonary Arterial Hypertension
ALPHA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowALPHA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ALPHA Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the overall participant count for this experiment?
"At present, this medical trial is not registering patients. The study was published on October 1st 2017 and updated most recently on March 7th 2022. For those who are seeking alternative studies, there are currently 749 clinical trials related to pulmonary arterial hypertension that are accepting participants as well as 3 studies involving allogeneic human cardiosphere-derived stem cells actively recruiting individuals."
Is this experiment currently seeking participants?
"Clinicaltrials.gov shows that this specific medical trial, initially posted on October 1st 2017 and last updated on March 7th 2022, is no longer looking for participants; however, there are currently 752 other trials actively recruiting patients."
Is this clinical trial enrolling participants over the age of sixty?
"The set of requirements to take part in this clinical trial requires that the participant is between 18 and 75 years. It was observed that 56 trials were conducted on those younger than 18 while 665 studies were administered for seniors aged 65 or more."
What potential risks exist with Allogeneic Human Cardiosphere-Derived Stem Cells?
"With minimal clinical evidence to support the safety and efficacy of Allogeneic Human Cardiosphere-Derived Stem Cells, this treatment was assigned a score of 1."
Does my profile meet the requirements for participation in this research study?
"This clinical trial is enlisting 26 individuals aged between 18 and 75 with pulmonary arterial hypertension. To be eligible, patients must have an oxygen saturation level of 90% or above at rest (either independent of supplemental O2 or not), a medically confirmed case of IPAH, HPAH, PAH-CTD, or PAH-HIYV being in either NYHA Functional Class II or III, 6MWD greater than 150m; they also need to have been on stable doses of certain pulmonary medications for four weeks prior to enrollment. Additionally all those with HIV need to be taking effective HAART regimens and the PC"
Have any prior experiments utilized Allogeneic Human Cardiosphere-Derived Stem Cells?
"Currently, there are three active research studies examining Allogeneic Human Cardiosphere-Derived Stem Cells with one study in its third phase. Multiple medical sites across 14 cities - such as Los Angeles, California - are conducting these investigations into this therapeutic treatment option."
Share this study with friends
Copy Link
Messenger